Conduct↦Safety↦Medicinal Product Safety Reporting↦Advanced Therapies
Was betrifft es? Warum ist das wichtig?
Advanced Therapies of Medical Products (ATMP) include Transplant Products (TrP), Gene Therapy (GT), and Genetically Modified Organisms (GMO).
In these studies:
- The ClinO ordinance and the definitions of IMP safety events apply
- Safety events are reported to:
- EC though BASEC
- Swissmedic via the Biovigilance division (e.g. not to the Swissmedic Clinical trial division)
TrP / GT / GMO causality follow IMP definitions. In addition events are linked to:
- The donation or preparation of the donation
- The contamination of the transplant or the GT / GMO as a final product
- A quality defect of the Trp / GT / GMO, its components, MD, or matrices as product components
- Serious events during the administration of a TrP / GT / GMO
- The accidental release of the GMO into the environment, or the transmission to other persons or animals
Mehr
Was muss ich befolgen?
As a Site-INV:
- Collect and report safety events as described in the protocol
- Report SAEs to the SP-INV within 24 hours of awareness
As a SP-INV:
- Re-assess safety events forwarded by the Site-INV
- Report all cases of deaths to EC and Swissmedic (e.g. risk category B and C studies), within 7 days
- Report SUSARs to EC and Swissmedic (e.g. only risk category B and C studies) within:
- 7 days, if fatal or life-threatening
- 15 days, for all other SUSARs
- In the event of a first pilot phase study, report all SADRs to Swissmedic within 15 days
AE documentation and reporting is mandatory during the course of a study. The defined reporting period for a particular study is documented in the study protocol (e.g. please refer to the protocol for the definition of your study reporting period). Usually it is mandatory once the participant has signed the ICF until:
- Study termination (e.g. last study participant at last study visit), or
- The end of some predefined safety follow-up period (e.g. as defined in the study protocol)
Wo kann ich Hilfe anfordern?
Your local Research Support Centre↧ can assist you with experienced staff regarding this topic
Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch
Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch
Bern, Department of Clinical Research (DCR), dcr.unibe.ch
Geneva, Clinical Research Center (CRC), crc.hug.ch
Lausanne, Clinical Research Center (CRC), chuv.ch
St. Gallen, Clinical Trials Unit (CTU), h-och.ch
Zürich, Clinical Trials Center (CTC), usz.ch
External Links
Swissmedic – see in particular
- Human medicine
- Transplant products
- Instructions /information sheets
- Biovigilance devision (biovigilance@swissmedic.ch)
- Information sheet
- I-315.AA.03-A04e Mandatory reporting of adverse reactions during clinical trials with TrP / GT / GMO
Swiss Law
ClinO – see in particular articles
- Art. 21 Studies of TrP
- Art. 22 Studies of GT and GMO
- Art. 40 SAE in IMP studies
- Art. 41 SUSAR in IMP studies